Biology of Blood and Marrow Transplantation
Volume 13, Issue 7 , Pages 814-821 , July 2007

Allogeneic Transplantation for Adult Acute Leukemia in First and Second Remission with a Novel Regimen Incorporating Daily Intravenous Busulfan, Fludarabine, 400 CGY Total-Body Irradiation, and Thymoglobulin

  • James A. Russell

      Affiliations

    • Alberta Blood and Bone Marrow Transplant Program and Departments of Oncology, Foothills Hospital, Alberta, Canada
    • Tom Baker Cancer Centre, Calgary
    • Corresponding Author InformationCorrespondence and reprint requests: James A. Russell, FRCP, Department of Medicine, Tom Baker Cancer Centre, 1331-29th St. N.W., Calgary, Alberta, Canada T2N 4N2.
    • ,
  • Mary Lynn Savoie

      Affiliations

    • Alberta Blood and Bone Marrow Transplant Program and Departments of Oncology, Foothills Hospital, Alberta, Canada
    • Tom Baker Cancer Centre, Calgary
    • ,
  • Alexander Balogh

      Affiliations

    • Alberta Blood and Bone Marrow Transplant Program and Departments of Oncology, Foothills Hospital, Alberta, Canada
    • Tom Baker Cancer Centre, Calgary
    • ,
  • A. Robert Turner

      Affiliations

    • Cross Cancer Institute, Edmonton, Alberta, Canada
    • ,
  • Loree Larratt

      Affiliations

    • Cross Cancer Institute, Edmonton, Alberta, Canada
    • ,
  • M. Ahsan Chaudhry

      Affiliations

    • Alberta Blood and Bone Marrow Transplant Program and Departments of Oncology, Foothills Hospital, Alberta, Canada
    • Tom Baker Cancer Centre, Calgary
    • ,
  • Jan Storek

      Affiliations

    • Alberta Blood and Bone Marrow Transplant Program and Departments of Oncology, Foothills Hospital, Alberta, Canada
    • Tom Baker Cancer Centre, Calgary
    • ,
  • Nizar J. Bahlis

      Affiliations

    • Alberta Blood and Bone Marrow Transplant Program and Departments of Oncology, Foothills Hospital, Alberta, Canada
    • Tom Baker Cancer Centre, Calgary
    • ,
  • Christopher B. Brown

      Affiliations

    • Alberta Blood and Bone Marrow Transplant Program and Departments of Oncology, Foothills Hospital, Alberta, Canada
    • Tom Baker Cancer Centre, Calgary
    • ,
  • Diana Quinlan

      Affiliations

    • Alberta Blood and Bone Marrow Transplant Program and Departments of Oncology, Foothills Hospital, Alberta, Canada
    • Tom Baker Cancer Centre, Calgary
    • ,
  • Michelle Geddes

      Affiliations

    • Alberta Blood and Bone Marrow Transplant Program and Departments of Oncology, Foothills Hospital, Alberta, Canada
    • Tom Baker Cancer Centre, Calgary
    • ,
  • Douglas A. Stewart

      Affiliations

    • Alberta Blood and Bone Marrow Transplant Program and Departments of Oncology, Foothills Hospital, Alberta, Canada
    • Tom Baker Cancer Centre, Calgary

Received 16 January 2007 ,Accepted 6 March 2007.

References 

  1. Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol. 2002;118:385–400
  2. Burnett AK. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?—An adult treater’s view [annotation]. Br J Haematol. 2002;118:357–364
  3. Hahn T, Wall D, Camitta B, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant. 2006;12:1–30
  4. Watson M, Buck G, Wheatley K, et al. Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients; analysis of the UK Medical Research Council AML 10 Trial. Eur J Cancer. 2004;40:971–978
  5. Sanders JE, Pritchard S, Mahoney P, et al. Growth and development following marrow transplantation for leukemia. Blood. 1986;68:1129–1135
  6. Cohen A, Rovelli A, Van-Lint M-T, et al. Final height of patients who underwent bone marrow transplantation during childhood. Arch Dis Child. 1996;74:437–440
  7. Blaise D, Maraninchi D, Archimbaud E, et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d’Etudes de la Greffe de Moelle Osseuse. Blood. 1992;79:2578–2582
  8. Blaise D, Maraninchi D, Michallet M, et al. Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission. Blood. 2001;97:3669–3671
  9. Ringden O, Remberger M, Ruutu T, et al. Nordic Bone Marrow Transplantation Group Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Blood. 1999;93:2196–2201
  10. Socie G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia:long-term follow-up of 4 randomized studies. Blood. 2001;98:3569–3574
  11. Ringden O, Labopin M, Tura S, et al. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Br J Haematol. 1996;93:637–645
  12. Michel G, Gluckman E, Esperou-Bourdeau H, et al. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation—a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol. 1994;12:1217–1222
  13. Litzow MR, Perez WS, Klein JP, et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol. 2002;119:1115–1124
  14. Hartman AR, Williams SF, Dillon JJ. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant. 1998;22:439–443
  15. Yanada M, Naoe T, Iida H, et al. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplant. 2005;36:867–872
  16. Heinzelmann F, Ottinger H, Muller CH, et al. Total-body irradiation—role and indications: results from the German Registry for Stem Cell Transplantation (DRST). Strahlenther Onkol. 2006;182:222–230
  17. Bunin N, Aplenc R, Kamani N, et al. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant. 2003;32:543–548
  18. Granados E, de La Camara R, Madero L, et al. Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long term event-free survival with conditioning regimens containing total body irradiation. Haematologica. 2000;85:1060–1067
  19. Davies SM, Ramsay NK, Klein JP, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol. 2000;18:340–347
  20. Andersson BS, Gajewski J, Donato M, et al. Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Bone Marrow Transplant. 25(Suppl 2):S35-S38.
  21. Kashyap A, Wingard J, Cagnoni P, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant. 2002;8:493–500
  22. Thall PF, Champlin RE, Andersson BS, et al. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects. Bone Marrow Transplant. 2004;33:1191–1199
  23. de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104:857–864
  24. Savoie ML, Balogh A, Chaudhry MA, et al. Total body irradiation (TBI) added to fludarabine/busulfan/antithymocyte globulin (FLUBUP/ATG) conditioning increases overall survival and relapse-free survival in patients with acute myeloid leukemia (AML) receiving allogeneic stem cell transplants. Blood. 2006;108:854a
  25. Russell JA, Chaudhry A, Booth K, et al. Early outcomes after allogeneic stem cell transplantation for leukemia and myelodysplasia without protective isolation: a 10-year experience. Biol Blood Marrow Transplant. 2000;6:109–114
  26. Russell JA, Woodman RC, Poon M-C, et al. Addition of low-dose folinic acid to a methotrexate/cyclosporin regimen for prevention of acute graft-versus-host disease. Bone Marrow Transplant. 1994;14:397–401
  27. Barrett J. Graft-versus-host disease. In:  Treleaven J,  Barrett J editor. Bone Marrow Transplantation in Practice. Edinburgh: Churchill Livingstone; 1992;p. 257
  28. Blume KG, Kopecky KJ, Henslee-Downey JP, et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. Blood. 1993;81:2187–2193
  29. Snyder DS, Chao NJ, Amylon MD, et al. Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. Blood. 1993;82:2920–2928
  30. Marks DI, Forman SJ, Blume KG, et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant. 2006;12:438–453
  31. Kroger N, Kruger W, Wacker-Backhaus G, et al. Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant. 1998;22:1029–1033
  32. Zander AR, Berger C, Kroger N, et al. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Clin Cancer Res. 1997;3:2671–2675
  33. Woods WG, Ramsay NK, Weisdorf DJ, et al. Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside:lack of superiority over cyclophosphamide-containing conditioning regimens. Bone Marrow Transplant. 1990;6:9–16
  34. Kanda Y, Sakamaki H, Sao H, et al. Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelated donor. Biol Blood Marrow Transplant. 2005;11:881–889
  35. Alyea E, Neuberg D, Mauch P, et al. Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2002;8:139–144
  36. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 1990;76:1867–1871
  37. Geddes M, Kangarloo SB, Naveed F. High busulfan exposure is associated with worse outcome in a daily iv busulfan and fludarabine transplant regimen. Blood. 2006;108:97a
  38. Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002;8:468–476
  39. Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia. 2006;20:128–135
  40. Banna GL, Aversa S, Sileni VC, et al. Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens. Crit Rev Oncol Hematol. 2004;51:171–189
  41. Russell JA, Larratt L, Brown C, et al. Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: influence of stem cell source on outcome. Bone Marrow Transplant. 1999;24:1177–1183
  42. Russell JA, Turner AR, Larratt L, et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant. 2007;13:299–306
  43. Bacigalupo A, Lamparelli T, Barisione , et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006;12:560–565
  44. Deeg HJ, Storer BE, Boeckh M, et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant. 2006;12:573–584
  45. Dahlke J, Kroger N, Zabelina T, et al. Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation. Bone Marrow Transplant. 2006;37:155–163
  46. Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997;15:1767-1767
  47. Alyea EP, Weller E, Fisher DC, et al. Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2002;8:601–607
  48. Kiehl MG, Kraut L, Schwerdtfeger R, et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol. 2004;22:2816–2825
  49. Ottinger HD, Ferencik S, Beelen DW, et al. Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched related donors, and HLA-matched unrelated donors. Blood. 2003;102:1131–1137

PII: S1083-8791(07)00197-8

doi: 10.1016/j.bbmt.2007.03.003

Biology of Blood and Marrow Transplantation
Volume 13, Issue 7 , Pages 814-821 , July 2007

Article Tools

* Image Usage & Resolution